Blue Jet Healthcare Moat Analysis: Score & Risks
Blue Jet Healthcare Ltd.
A first-pass moat teardown of Blue Jet Healthcare Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Blue Jet Healthcare Ltd. scores 5.15 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“We develop, manufacture and market saccharin and its salts through a backward-integrated process designed for cost efficiency and environmental sustainability—with zero by-products.”
“The company secures business through multi-year / annual contracts in the CDMO business, thereby ensuring continuity of business in the medium to long term.”
“Launched a new product in the PI/API segment for a cardiovascular innovator, with scale-up benefits in the pharmaceutical intermediate expected to be realised in the next financial year”
“for this pharma intermediate today, we are at 60%-65%. Overall I would say we are at about 75% across all segments”
“Our capacities are often co-engineered and built to suit, to support our go-to-market strategy for customers who are mostly innovator and CDMO companies.”
“Supply Disruptions, incurring supplier due diligence and monitoring cost, increased overall cost”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion